Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Dec 14, 2020 7:36pm
73 Views
Post# 32105831

RE:RE:RE:RE:RE:RE:AGN halted

RE:RE:RE:RE:RE:RE:AGN haltedYou would think that with the study requiring a period of 3 months/patient that those selected could have begun the trial.  Those to be selected could have been given a patient trial number to which a patient could be assigned later.

If they could not start the study until ALL patients are enrolled, then how can they complete the study and have results by mid 2021? The investor presentation does not show a change in the results date for top line results. Perhaps the wording on the NR is not accurate.

prophetoffacts wrote:

It is not clear that a single patient has even been treated yet. As reported in the November 27, 2020 news release after the COVID delays enrollment of the trial had recommenced and subjects had been randomised to a trial arm. No mention treatments have been administered to anyone yet.  

  • "Resumed enrollment of patients for the clinical trial with beta glucan as a cholesterol reducing natural pharmaceutical product. 191 patients have been screened and 65 randomized during the last three months." news release


<< Previous
Bullboard Posts
Next >>